Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2020-07-07 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Alteogen regarding a 'Decision on Bonus Issue' (무상증자결정). In the context of Korean corporate filings, a bonus issue (free share issuance) is a capital change event. Since the document details the issuance of new shares to existing shareholders, it falls under the category of Share Issue/Capital Change.
2020-07-07 Korean
주권매매거래정지(무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding a temporary suspension of stock trading for 'Alteogen' due to a bonus issue (free share issuance). It cites KOSDAQ market regulations and specifies the duration of the suspension. Since it is a regulatory announcement regarding market operations and does not fit into specific categories like share issuance or dividend announcements, it falls under the general regulatory filing category.
2020-07-07 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory announcement regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for a bonus issue (free share distribution). This type of corporate action announcement, which does not fit into specific categories like dividends or share buybacks, is a standard regulatory filing in the Korean market (KRX).
2020-07-07 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming 'Corporate Presentation' (IR meeting) scheduled for July 9, 2020. It details the date, location, purpose, and agenda of the meeting. Since this is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of an investor relations activity, it fits the definition of a Regulatory Filing (RNS) or a general announcement of an event.
2020-06-30 Korean
투자판단관련주요경영사항(인간 히알루로니다제 원천 기술(ALT-B4) 비독점적 라이센스 계약 체결)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Alteogen) regarding a 'Major Management Matter' (주요경영사항), specifically a technology licensing agreement (ALT-B4). This type of disclosure, which details material business contracts, partnerships, or licensing deals, is classified under 'Regulatory Filings' (RNS) as it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or other specialized financial reports.
2020-06-24 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation for executives falls under the category of regulatory filings that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes). Therefore, it is classified as a general Regulatory Filing (RNS).
2020-06-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.